Goldman Sachs
TRDA icon

Goldman Sachs’s Entrada Therapeutics TRDA Stock Holding History

Goldman Sachs’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
177,343
-35,437
-17% -$340K ﹤0.01% 5008
2026
Q1 		$2.69M Buy
212,780
+7,607
+4% +$87.2K ﹤0.01% 4265
2025
Q4 		$2.11M Sell
205,173
-17,163
-8% -$145K ﹤0.01% 4540
2025
Q3 		$1.29M Buy
222,336
+138,186
+164% +$808K ﹤0.01% 4853
2025
Q2 		$565K Sell
84,150
-8,390
-9% -$67.5K ﹤0.01% 5090
2025
Q1 		$837K Sell
92,540
-192,732
-68% -$2.4M ﹤0.01% 4823
2024
Q4 		$4.93M Buy
285,272
+200,806
+238% +$3.64M ﹤0.01% 3468
2024
Q3 		$1.35M Buy
84,466
+51,164
+154% +$806K ﹤0.01% 4433
2024
Q2 		$475K Buy
33,302
+15,979
+92% +$227K ﹤0.01% 4864
2024
Q1 		$245K Sell
17,323
-741
-4% -$10.5K ﹤0.01% 5045
2023
Q4 		$273K Buy
18,064
+5,260
+41% +$77.9K ﹤0.01% 5045
2023
Q3 		$202K Sell
12,804
-8,532
-40% -$134K ﹤0.01% 5043
2023
Q2 		$323K Sell
21,336
-25,840
-55% -$356K ﹤0.01% 4979
2023
Q1 		$684K Sell
47,176
-354,863
-88% -$4.74M ﹤0.01% 4645
2022
Q4 		$5.44M Sell
402,039
-47,954
-11% -$841K ﹤0.01% 3090
2022
Q3 		$7.09M Buy
449,993
+4,307
+1% +$54.7K ﹤0.01% 2831
2022
Q2 		$5.43M Buy
445,686
+231
+0.1% +$1.75K ﹤0.01% 3062
2022
Q1 		$4.18M Hold
445,455
– – ﹤0.01% 3509
2021
Q4 		$7.63M Buy
+445,455
New +$10.8M ﹤0.01% 3009

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Goldman Sachs's TRDA Position: Q2 2026 in Review

Goldman Sachs reduced its Entrada Therapeutics (TRDA) stake by 17% in Q2 2026, selling an estimated $340K and leaving 177,343 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5008.

Goldman Sachs first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $7.63M in Q4 2021. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Goldman Sachs held 177,343 shares of Entrada Therapeutics worth $1.31M as of Q2 2026.
  • Goldman Sachs sold 35,437 Entrada Therapeutics shares in Q2 2026, an estimated $340K.
  • Entrada Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5008 holding.
  • Goldman Sachs first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Entrada Therapeutics position peaked at $7.63M in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.